03.19.26 -- Advising The Biotech C-Suite To Reconsider Quality

Delve into the complexities of scaling decisions to gain insights from biopharma developers and a CDMO. Learn about their mutual interest in achieving successful scale-up and strategies.

Explore how to choose between single‑use and stainless‑steel bioreactors, outlining key advantages, limitations, and long‑term considerations essential for successful biologics scale‑up.

Strong IP protections drive Tennessee’s biotech growth by attracting investment, supporting research, fostering collaboration, and enabling innovators to deliver new therapies and technologies to patients.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

Access a thorough investigation that delves into the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.

CDMO selection requires evaluating experience, quality standards, and flexibility. Assess technical transfer skills, supply chain security, and collaborative approach for a reliable, long-term project fit.

Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.

Consider this manufacturing platform integrating perfusion bioreactors, continuous product capture, low pH viral inactivation, polishing, viral filtration, and formulation steps.

Uncover how Nu‑Tek’s plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

Partner with a CMO that combines expertise, innovation, and trusted global capabilities to bring life-changing therapies to patients faster and more reliably.

The journey of a novel bioconjugate into clinic is complex and uncertain. Examine the particular challenges when moving a bioconjugate candidate from early development into clinic.